EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Intranasal Anticholinergics for Treatment of Chronic Rhinitis: Systematic Review and Meta‐Analysis

Jonathan C Pang iD, Milind Vasudev iD, Amy T Du, Madeline M Nottoli, Katherine Dang, Edward C Kuan iD

The Laryngoscope · 2023-04 · 133 (4) · 722-731

DOI: 10.1002/lary.30306 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift The Laryngoscope, online erschienen am 15.07.2022. Verfasst von Jonathan C Pang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, California, USA. Hauptthemen laut MEDLINE: Rhinitis. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Topical intranasal anticholinergics are commonly prescribed for the relief of chronic rhinitis and associated symptoms, warranting thorough assessment of the supporting evidence. The present study aimed to evaluate the safety and efficacy of anticholinergic nasal sprays in the management of allergic and non‐allergic rhinitis symptom severity and duration.

Methods

A search encompassing the Cochrane Library, PubMed/MEDLINE, and Scopus databases was conducted. Primary studies describing rhinorrhea, nasal congestion, and/or postnasal drip outcomes in rhinitis patients treated with an anticholinergic spray were included for review.

Results

The search yielded 1,029 unique abstracts, of which 12 studies ( n = 2,024) met inclusion criteria for qualitative synthesis and 9 ( n = 1,920) for meta‐analysis. Median follow‐up was 4 weeks and ipratropium bromide was the most extensively trialed anticholinergic. Compared to placebo, anticholinergic treatment was demonstrated to significantly reduce rhinorrhea severity scores (standardized mean difference [95% CI] = −0.77 [−1.20, −0.35]; −0.43 [−0.72, −0.13]) and duration (−0.62 [−0.95, −0.30]; −0.29 [−0.47, −0.10]) in allergic and non‐allergic rhinitis patients respectively. Benefit was less consistent for nasal congestion, postnasal drip, and sneezing symptoms. Reported adverse effects included nasal mucosa dryness or irritation, epistaxis, headaches, and pharyngitis, though comparison to placebo found significantly greater risk for epistaxis only (risk ratio [95% CI] = 2.19 [1.22, 3.93]).

Conclusion

Albeit treating other symptoms with less benefit, anticholinergic nasal sprays appear to be safe and efficacious in reducing rhinorrhea severity and duration in both rhinitis etiologies. This evidence supports their continued use in the treatment of rhinitis‐associated rhinorrhea. Level of Evidence 1 Laryngoscope , 133:722–731, 2023

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhinitisHumansCholinergic AntagonistsNasal SpraysEpistaxisRhinorrhea

Stichwörter der Autor:innen

anticholinergicmeta-analysisrhinitisrhinorrheasystematic review

Substanzen

Cholinergic AntagonistsNasal Sprays

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, California, USA.

ORCID-Profile: Jonathan C Pang, Milind Vasudev, Edward C Kuan

Zitieren

APA

Pang, J. C., Vasudev, M., Du, A. T., Nottoli, M. M., Dang, K., & Kuan, E. C. (2023). Intranasal Anticholinergics for Treatment of Chronic Rhinitis: Systematic Review and Meta‐Analysis. The Laryngoscope, 133(4), 722-731. https://doi.org/10.1002/lary.30306

Vancouver

Pang JC, Vasudev M, Du AT, Nottoli MM, Dang K, Kuan EC. Intranasal Anticholinergics for Treatment of Chronic Rhinitis: Systematic Review and Meta‐Analysis. The Laryngoscope. 2023;133(4):722-731. doi:10.1002/lary.30306

BibTeX
@article{Pang2023,
  author = {Pang, Jonathan C and Vasudev, Milind and Du, Amy T and Nottoli, Madeline M and Dang, Katherine and Kuan, Edward C},
  title = {Intranasal Anticholinergics for Treatment of Chronic Rhinitis: Systematic Review and Meta‐Analysis},
  journal = {The Laryngoscope},
  year = {2023},
  volume = {133},
  number = {4},
  pages = {722--731},
  doi = {10.1002/lary.30306}
}
Kostenlos starten →